NDAINHALATIONSPRAY, METERED
Approved
Oct 2011
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
3
Mechanism of Action
RESPIMAT: COMBIVENT RESPIMAT is a combination of the anticholinergic ipratropium bromide and the beta 2 -adrenergic agonist albuterol sulfate. The mechanisms of action described below for the individual components apply to COMBIVENT RESPIMAT. The two classes of medications (an anticholinergic and a…
Indications (2)
Clinical Trials (3)
Ventilator Adapters for Combivent Respimat
Started Oct 2013
11 enrolled
Pulmonary Disease, Chronic Obstructive
Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
Started Nov 2009
470 enrolled
Pulmonary Disease, Chronic Obstructive
4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
Started Dec 2008
226 enrolled
Asthma
Loss of Exclusivity
LOE Date
Oct 16, 2030
56 months away
Patent Expiry
Oct 16, 2030